A carregar...
Interrupting Anticoagulation in Patients With Nonvalvular Atrial Fibrillation
Three target-specific oral anticoagulants (TSOACs)—dabigatran, rivaroxaban, and apixaban—have been approved by the FDA to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; however, no agents are currently approved to reverse the anticoagulant effects o...
Na minha lista:
Publicado no: | P T |
---|---|
Autor principal: | |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
MediMedia USA, Inc.
2014
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4264672/ https://ncbi.nlm.nih.gov/pubmed/25516695 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|